Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers
ViPOR Combination
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
What the film says
Multiple myeloma comes back, again and again, until the standard drug classes are exhausted. CAR T cells aimed at BCMA, a marker on myeloma cells, are approved and effective, but relapses follow.
The idea: an academic BCMA CAR T, built with a tighter grip on its target.
At the University Hospital in Dresden, a patient's own T cells receive a high-affinity receptor for BCMA, designed to bind the marker more firmly than earlier constructs. After conditioning chemotherapy, the cells are returned in a single infusion, at one of four rising dose levels.
CARLOTTA-01 is a first safety study, for myeloma after at least two prior lines and for some relapsed large B-cell lymphomas. Martin Wermke leads it. Public record; not medical advice.
Sources behind this film
Myeloma relapses through drug classes (IMiD, PI, anti-CD38); High-affinity BCMA CAR; Conditioning chemotherapy then single IV infusion; four dose levels; Myeloma and relapsed/refractory DLBCL cohorts; Martin Wermke; Dresden
The drug
Single-dose intravenous infusion of MDC-CAR-BCMA001 at the respective dose level following a conditioning chemotherapy
The study
The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.